111 related articles for article (PubMed ID: 6368246)
1. The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
Peter HH; Dziuba-Traber H; Boerner D
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):353-9. PubMed ID: 6368246
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
Bicker U
Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
[TBL] [Abstract][Full Text] [Related]
3. Immunorestoration of anergic cancer patients by azimexon.
Goutner A; Nasrat F; Bonardelle D; Rameau G
Recent Results Cancer Res; 1980; 75():47-52. PubMed ID: 7232839
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of intravenous azimexon therapy in human cancer.
Patt YZ; Hersh EM; Reuben J; Claghorn L; Mavligit G
J Biol Response Mod; 1986 Aug; 5(4):313-8. PubMed ID: 2874196
[TBL] [Abstract][Full Text] [Related]
5. Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
Mathé G; Florentin I; Bruley-Rosset M; Goutner A; Serrou B
Recent Results Cancer Res; 1982; 80():331-3. PubMed ID: 6977171
[No Abstract] [Full Text] [Related]
6. Effects of BM 12,531 (azimexon) on in vitro lymphocyte and macrophage proliferation.
Hadden JW; Coffey RG
Recent Results Cancer Res; 1980; 75():162-4. PubMed ID: 7232828
[TBL] [Abstract][Full Text] [Related]
7. In vivo immunomodulating properties of two synthetic agents: azimexon and tuftsin.
Florentin I; Schulz J; Bruley-Rosset M; Kiger N; Martinez J; Mathé G
Recent Results Cancer Res; 1980; 75():153-61. PubMed ID: 6894500
[TBL] [Abstract][Full Text] [Related]
8. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
9. Treatment of multiple myeloma: a randomized study of three different regimens.
Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
[TBL] [Abstract][Full Text] [Related]
10. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
Lee BJ; Sahakian G; Clarkson BD; Krakoff IH
Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
[No Abstract] [Full Text] [Related]
11. Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
Bicker U
Arzneimittelforschung; 1982; 32(7):746-52. PubMed ID: 6889876
[TBL] [Abstract][Full Text] [Related]
12. Effect of azimexon (BM 12.531) on mouse granulocyte-macrophage and monocyte-macrophage progenitor cells.
Jeng JC; McCarthy KF; Chirigos MA; Weiss JF
Experientia; 1982 Jan; 38(1):132-4. PubMed ID: 7056357
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by Azimexon.
Kreienberg R; Boerner D; Melchert F; Lemmel EM
J Immunopharmacol; 1983; 5(1-2):49-64. PubMed ID: 6606686
[TBL] [Abstract][Full Text] [Related]
14. Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon.
Patt YZ; Mavligit GM; Reuben J; Mansell PW; Li S; Newell G; Talpaz M; Hersh EM
J Biol Response Mod; 1986 Jun; 5(3):263-9. PubMed ID: 3088215
[TBL] [Abstract][Full Text] [Related]
15. [Biological effects of leakadin].
Garin AM; Lichinitser MR; Dmitrieva NV; Rubtsov BI; Leneva NV
Vopr Onkol; 1988; 34(2):192-6. PubMed ID: 2964757
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
[TBL] [Abstract][Full Text] [Related]
17. Structural studies of immunomodulators. Part 2: Crystal structure and conformation of azimexon (BM 12.531) an immunostimulant and an anti-tumor drug.
Srikrishnan T
Anticancer Drug Des; 1990 May; 5(2):213-20. PubMed ID: 2357266
[TBL] [Abstract][Full Text] [Related]
18. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.
Kay NE; Oken MM; Kyle R; Van Ness B; Kalish L; Leong T; Greipp P
Leuk Lymphoma; 1995 Jan; 16(3-4):351-4. PubMed ID: 7719242
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
